Recon: Lilly’s experimental ‘triple G’ drug achieves 24% weight loss in Phase 2; Merck, Ridgeback withdraw EU COVID drug application
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy